MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene regulation. More than two thousand human miRNAs have been identified thus far. These bind imperfectly to the 3’-untranslated region of target mRNA and have been involved in several pathological conditions including cancer. In fact, major hallmarks of cancer, such as the cell cycle, cell proliferation, survival and invasion are modulated by miRNAs. Cancer drug resistance (CDR) has also been described as being modulated by miRNAs. CDR remains a burden for cancer therapy and patients’ outcome, often resulting in more aggressive tumours that tend to metastasize to distant organs. In this review we discuss the role of miRNAs influencing drug metaboli...
MicroRNA (miRNAs), a class of small, endogenous non-coding RNA molecules of about 21-24 nucleotides ...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
One of the major challenges in the treatment of lung cancer is the development of drug resistance. T...
MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene reg...
MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene reg...
MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene reg...
Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can reg...
Chemoresistance is one of the main problems in the therapy of cancer. There are a number of differen...
MicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathw...
MicroRNAs (miRNAs) are 20-22 nucleotides long small non-coding RNAs that regulate gene expression po...
Drug resistance remains a major problem in the treatment of cancer patients for both conventional ch...
Cancer chemotherapy may induce a multidrug resistance (MDR) phenotype. The development of MDR is bas...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
MicroRNAs (miRNAs) are a group of endogenous, small noncoding RNAs of approximately 22 nucleotides i...
MicroRNA (miRNAs), a class of small, endogenous non-coding RNA molecules of about 21-24 nucleotides ...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
One of the major challenges in the treatment of lung cancer is the development of drug resistance. T...
MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene reg...
MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene reg...
MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene reg...
Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can reg...
Chemoresistance is one of the main problems in the therapy of cancer. There are a number of differen...
MicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathw...
MicroRNAs (miRNAs) are 20-22 nucleotides long small non-coding RNAs that regulate gene expression po...
Drug resistance remains a major problem in the treatment of cancer patients for both conventional ch...
Cancer chemotherapy may induce a multidrug resistance (MDR) phenotype. The development of MDR is bas...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
MicroRNAs (miRNAs) are a group of endogenous, small noncoding RNAs of approximately 22 nucleotides i...
MicroRNA (miRNAs), a class of small, endogenous non-coding RNA molecules of about 21-24 nucleotides ...
Development of drug resistance has considerably limited the efficacy of cancer treatments, including...
One of the major challenges in the treatment of lung cancer is the development of drug resistance. T...